|
|
Post by sweedee79 on Sept 5, 2021 18:14:35 GMT -5
If they don’t study the science they won’t understand the less risk of hypo. This is why we have to train our own providers, if you want to work for us you follow the protocols. The results of this training is pure amazement! You are exactly right Sports... I'm cautiously optimistic about pediatric trials and if that will change the tide or not.... Docs are quite entrenched in how they do things... So it is my opinion that Mnkd should begin a working relationship with Vdex.. . Why not? Business is very much about building relationships IMO... We need to bury the hatchet and work together because we all want Afrezza to succeed!!! Why not fight the battle on all fronts 🙏🙏🙏 |
|
|
|
Post by agedhippie on Sept 5, 2021 19:00:30 GMT -5
The paradigm shift needs to occur before patent expiration....I believe Al Mann gave a speech regarding this very problem. High pricing is needed to recoup R & D costs before generics seize the day. It reminds me of the book "The Red Queen". The cost they are trying to recoup are for Technosphere, it's just that until now Afrezza was the only drug so it had to bear all the costs. With TreT coming on line that will no longer be the case and the price can be lowered to a point where it is comparable with RAA for the insurers. |
|
|
|
Post by sportsrancho on Sept 5, 2021 19:01:28 GMT -5
If they don’t study the science they won’t understand the less risk of hypo. This is why we have to train our own providers, if you want to work for us you follow the protocols. The results of this training is pure amazement! You are exactly right Sports... I'm cautiously optimistic about pediatric trials and if that will change the tide or not.... Docs are quite entrenched in how they do things... So it is my opinion that Mnkd should begin a working relationship with Vdex.. . Why not? Business is very much about building relationships IMO... We need to bury the hatchet and work together because we all want Afrezza to succeed!!! Why not fight the battle on all fronts 🙏🙏🙏 Cooperation is welcome from our end. Agree, regardless of the results from the peds trial, which will be mainly type 1s, the training of docs IS A BIG PART OF THE PROBLEM and the peds trial won’t change that. So the Type 2 market which is where the big market for Afrezza is, will continue as before and Afrezza will languish. |
|
|
|
Post by sweedee79 on Sept 5, 2021 20:02:22 GMT -5
The paradigm shift needs to occur before patent expiration....I believe Al Mann gave a speech regarding this very problem. High pricing is needed to recoup R & D costs before generics seize the day. It reminds me of the book "The Red Queen". The cost they are trying to recoup are for Technosphere, it's just that until now Afrezza was the only drug so it had to bear all the costs. With TreT coming on line that will no longer be the case and the price can be lowered to a point where it is comparable with RAA for the insurers. Thanks for that info... Good to know |
|
|
|
Post by beardawg on Sept 9, 2021 12:13:44 GMT -5
If you’re thinking this will take years, you are correct. Is it worth it? Afrezza is provably better than Novolog and Humalog. CGMs will prove it. Take a look at how much money is spent on Humalog and Novolog and imagine Mannkind getting half of it, or more. That’s the prize. At first glance I was thinking you meant "probably", lol. |
|
|
|
Post by mango on Sept 9, 2021 12:16:25 GMT -5
The most important feature of Afrezza is its ability to restore post-prandial glucose homeostasis. It’s through Afrezza’s remarkable, one-of-a-kind pharmacokinetics that enables Afrezza to mimic endogenous first-phase insulin secretion like that seen in a healthy, non-diabetic pancreas.
The first-phase insulin response is a homeostatic mechanism that’s critical to maintaining glucose homeostasis. In response to rising blood glucose levels from a meal, a short, robust burst of insulin is released. This initial release is an imprecise amount, and is regulated by beta cell memory. The magic of the first-phase insulin response comes to follow, by promoting peripheral uptake of the prandial nutrient load, suppressing hepatic glucose production, and blunting the rise of postprandial blood glucose.
This is what Afrezza does. Afrezza restores post-prandial glucose homeostasis via mimicking the first-phase insulin pharmacokinetics.
Afrezza is nothing short of a masterpiece.
|
|
